OMH
Ohmyhome Ltd
$0.6050
+4.49%
$13.4M
No data for this timeframe.
Vol
Market Cap$13.4M
Cap SizeNano Cap
SEC Reports2
Exchange Nasdaq·Sector Real Estate Agents & Managers (For Others)·Inc. E9·CIK 0001944902·Prev Close $0.5790
Recent Activity
Apr 28, 2026
SEC
Ohmyhome Ltd filed its annual report (20-F) for FY2025, reporting total revenue of S$12.2M (+12.5% YoY) but a net loss o
20-F — Impact 7/10
Apr 24, 2026
SEC
Ohmyhome Ltd appointed its current CEO, Mr. Agus Prasetyo, as Acting Chief Financial Officer effective April 23, 2026, c
6-K — Impact 3/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
4Sell
1Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 16, 2025 | Maxim Group | DOWNGRADE | Buy → Hold |
| Sep 27, 2024 | Maxim Group | MAINTAIN | Buy → Buy |
| Mar 21, 2024 | Maxim Group | INITIATE | Buy |
Latest Reports
BEARISH
20-F
7/10
Ohmyhome Ltd filed its annual report (20-F) for FY2025, reporting total revenue of S$12.2M (+12.5% YoY) but a net loss o
Apr 28, 2026
NEUTRAL
6-K
3/10
Ohmyhome Ltd appointed its current CEO, Mr. Agus Prasetyo, as Acting Chief Financial Officer effective April 23, 2026, c
Apr 24, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jun 2025): 0% buy across 8 analysts — 0 strong buy, 0 buy, 3 hold, 4 sell, 1 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 16, 2025 | Maxim Group | DOWNGRADE | Buy | Hold |
| Sep 27, 2024 | Maxim Group | MAINTAIN | Buy | Buy |
| Mar 21, 2024 | Maxim Group | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 4 | 1 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.